Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates

• Published in: PloS one 2023-11, Vol.18 (11), p.e0294287-e0294287
• Main Authors: Chatupheeraphat, Chawalit, Peamchai, Jiratchaya, Luk-in, Sirirat, Yainoy, Sakda, Eiamphungporn, Warawan
• Format: Article
• Language: English
• Subjects: Amino acids; Antibacterial activity; Antibiotics; Antiinfectives and antibacterials; Antimicrobial agents; Antimicrobial peptides; Bacteria; Bacterial infections; Bacterial pneumonia; Care and treatment; Ceftazidime; Cells; Chloramphenicol; Chloromycetin; Ciprofloxacin; Clinical isolates; Colistin; Cytotoxicity; Drug resistance; Drug resistance in microorganisms; E coli; Escherichia coli; Evaluation; Gram-negative bacteria; Health aspects; Heat resistance; High temperature; Infections; Klebsiella; Klebsiella pneumoniae; Mammalian cells; Meropenem; Minimum inhibitory concentration; Pathogens; Peptides; Physiological aspects; Physiology; Pneumonia; Public health administration; Rifampin; Sheep; Synergism; Synergistic effect
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0294287

Drug-resistant Enterobacterales infections are a great health concern due to the lack of effective treatments. Consequently, finding novel antimicrobials or combining therapies becomes a crucial approach in addressing this problem. BP203 and MAP-0403 J-2, novel antimicrobial peptides, have exhibited effectiveness against Gram-negative bacteria. In this study, we assessed the in vitro antibacterial activity of BP203 and MAP-0403 J-2, along with their synergistic interaction with conventional antibiotics including colistin, rifampicin, chloramphenicol, ceftazidime, meropenem, and ciprofloxacin against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates. The minimal inhibitory concentrations (MIC) of BP203 and MAP-0403 J-2 against tested E. coli isolates were 2-16 and 8-32 [mu]g/mL, respectively. However, for the majority of K. pneumoniae isolates, the MIC of BP203 and MAP-0403 J-2 were >128 [mu]g/mL. Notably, our results demonstrated a synergistic effect when combining BP203 with rifampicin, meropenem, or chloramphenicol, primarily observed in most K. pneumoniae isolates. In contrast, no synergism was evident between BP203 and colistin, chloramphenicol, ceftazidime, rifampicin, or ciprofloxacin when tested against all E. coli isolates. Furthermore, synergistic effects between MAP-0403 J-2 and rifampicin, ceftazidime or colistin were observed against the majority of E. coli isolates. Similarly, the combined effect of MAP-0403 J-2 with rifampicin or chloramphenicol was synergistic in the majority of K. pneumoniae isolates. Importantly, these peptides displayed the stability at high temperatures, across a wide range of pH values, in specific serum concentrations and under physiological salt conditions. Both peptides also showed no significant hemolysis and cytotoxicity against mammalian cells. Our findings suggested that BP203 and MAP-0403 J-2 are promising candidates against colistin-resistant E. coli. Meanwhile, the synergism of these peptides and certain antibiotics could be of great therapeutic value as antimicrobial drugs against infections caused by colistin-resistant E. coli and K. pneumoniae.